RBFOX2 and breast carcinoma: Interestingly, a switch between RBFOX2 (also called RBM9) and ESRP1/2 splicing factors has been involved in epithelial to mesenchymal transition (EMT) (25), and EMT was previously found associated with Doxo resistance in breast cancer (26–28).